Linrodostat

Linrodostat (development code BMS-986205) is an experimental drug being studied for its immunomodulating and antineoplastic activities.^[1]

Linrodostat

Clinical data
Other names	BMS-986205; ONO 7701
Routes of administration	Oral
Legal status
Legal status	Investigational
Identifiers
IUPAC name (2R)-N-(4-Chlorophenyl)-2-[(1s,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl]propanamide
CAS Number	1923833-60-6
DrugBank	DB14986
ChemSpider	58828674
UNII	0A7729F42K
Chemical and physical data
Formula	C24H24ClFN2O
Molar mass	410.92 g·mol−1
3D model (JSmol)	Interactive image
SMILES FC1=CC=2C(=CC=NC2C=C1)[C@@H]3CC[C@]([C@H](C(NC4=CC=C(Cl)C=C4)=O)C)(CC3)[H]
InChI InChI=1S/C24H24ClFN2O/c1-15(24(29)28-20-9-6-18(25)7-10-20)16-2-4-17(5-3-16)21-12-13-27-23-11-8-19(26)14-22(21)23/h6-17H,2-5H2,1H3,(H,28,29)/t15-,16-,17+/m1/s1 Key:KRTIYQIPSAGSBP-ZACQAIPSSA-N

Linrodostat is an inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1).^[2][3]

Linrodostat has entered clinical trials for a variety of cancer types including bladder cancer, head and neck cancer, endometrial cancer, gastric cancer, malignant melanoma, liver cancer, non-small cell lung cancer, and solid tumors.^[4]